Results 251 to 260 of about 170,525 (342)

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

Correction: Exploring the mechanisms of tetrahydrocurcumin in ameliorating nonalcoholic steatohepatitis based on network pharmacology and gut microbiota analysis <i>in vivo</i> and <i>in vitro</i>. [PDF]

Front Microbiol
Chen K, Wang J, Luo S, Quan Y, Wei P, Fu J, Ma J, Yang Y, Liu Y, Gao Z.   +9 more
europepmc   +1 more source

Paeonol Attenuates Nonalcoholic Steatohepatitis by Regulating Intestinal Flora and AhR/NLRP3/Caspase-1 Metabolic Pathway

Guiming Yan, Luning Zhang, Daqiang Wu, Shengnan Jiang, Qifeng Wu, Min Dai   +5 more
openalex   +1 more source

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L. R. Brouwer, Sibylle Neuhoff   +5 more
wiley   +1 more source

Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. [PDF]

World J Gastroenterol
Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J.   +9 more
europepmc   +1 more source

Poster presented at AASLD 2025: Progression to cirrhosis in people with metabolic dysfunction-associated steatohepatitis (MASH) in real-world cohorts in the US and Japan

Schattenberg, Jörn M., Aponte-Torres, Zuleika, Herrera, Ronald, Raluy, Mireia, Yates Mark, Younes Ramy, Sartini, Claudio   +6 more
openalex   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Phytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.

Cell Metabolism, 2019
Rie Ouchi, Shodai Togo, M. Kimura, T. Shinozawa, Masaru Koido, H. Koike, Wendy L Thompson, Rebekah A. Karns, C. Mayhew, P. McGrath, H. McCauley, Ran-ran Zhang, Kyle Lewis, Shoyo Hakozaki, Autumn Ferguson, Norikazu Saiki, Yosuke Yoneyama, I. Takeuchi, Y. Mabuchi, C. Akazawa, H. Yoshikawa, James M. Wells, T. Takebe   +22 more
semanticscholar   +1 more source

Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography

Rheumatology &Autoimmunity, EarlyView.
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan, Soonthorn Chonprasertsuk, Sith Siramolpiwat, Kanon Jatuworapruk   +3 more
wiley   +1 more source

Hepatic Mechanisms of Myocardial Infarction: A New Perspective in Metabolic Dysfunction-Associated Fatty Liver Disease. [PDF]

J Am Heart Assoc
Cui J, Wang W, Xu Q, Zhu M, Li Y, Liu Y, Liu Y.   +6 more
europepmc   +1 more source